Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Aclaris Therapeutics Inc (ACRS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ACRS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 4.95% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 171.96M USD | Price to earnings Ratio - | 1Y Target Price 9.83 |
Price to earnings Ratio - | 1Y Target Price 9.83 | ||
Volume (30-day avg) 963497 | Beta 0.5 | 52 Weeks Range 0.95 - 5.17 | Updated Date 03/30/2025 |
52 Weeks Range 0.95 - 5.17 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -152.75% |
Management Effectiveness
Return on Assets (TTM) -15.72% | Return on Equity (TTM) -84.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 53275793 | Price to Sales(TTM) 9.19 |
Enterprise Value 53275793 | Price to Sales(TTM) 9.19 | ||
Enterprise Value to Revenue 2.85 | Enterprise Value to EBITDA 0.28 | Shares Outstanding 108148000 | Shares Floating 66075457 |
Shares Outstanding 108148000 | Shares Floating 66075457 | ||
Percent Insiders 2.65 | Percent Institutions 82.48 |
Analyst Ratings
Rating 4.14 | Target Price 10 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aclaris Therapeutics Inc
Company Overview
History and Background
Aclaris Therapeutics, Inc. was founded in 2012. It's a biopharmaceutical company focused on developing novel treatments for immuno-inflammatory diseases. It has evolved from focusing solely on dermatology to a broader range of immune-related conditions.
Core Business Areas
- Immun-inflammatory disease segment: Developing novel treatments for immuno-inflammatory diseases. Focusing on oral and topical treatments targeting key pathways in immuno-inflammatory diseases.
Leadership and Structure
The leadership team includes Neal Walker as President and CEO. The company has a board of directors overseeing its operations.
Top Products and Market Share
Key Offerings
- Zunseogep: Aclaris Therapeutics is developing Zunseogep, a novel oral MK2 inhibitor, as a potential treatment for hidradenitis suppurativa (HS) and other immuno-inflammatory diseases. Specific market share data for Zunseogep is currently unavailable as it is in clinical development. Competitors depend on indications and success. Competitors in Hidradenitis Suppurativa include AbbVie (Humira), Novartis (Cosentyx), and various companies developing new therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovative. There is a growing demand for treatments for immuno-inflammatory diseases.
Positioning
Aclaris Therapeutics is positioned as a developer of novel treatments for immuno-inflammatory diseases, focusing on unmet medical needs. Its competitive advantage lies in its focus on novel targets and oral therapies.
Total Addressable Market (TAM)
The total addressable market (TAM) for immuno-inflammatory disease treatments is substantial, estimated to be worth tens of billions of dollars globally, and is projected to keep growing. Aclaris is positioned to tap into a portion of this TAM with their focus on novel therapies and new routes of administration.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Focus on immuno-inflammatory diseases
- Experienced management team
- Oral and topical drug delivery platforms
Weaknesses
- Limited product portfolio
- Reliance on clinical trial success
- Limited commercialization experience
- Dependence on financing
Opportunities
- Expansion of pipeline
- Partnerships and collaborations
- Expansion into new indications
- Potential for market exclusivity
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- LLY
Competitive Landscape
Aclaris Therapeutics faces competition from larger, more established pharmaceutical companies with greater resources. Its advantages include its focus on novel therapies and oral formulations. Disadvantages include its limited product portfolio and dependence on clinical trial success.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are dependent on revenue from marketed products and the progress of the drug pipeline. Aclaris Therapeutics has shifted its focus over time, which impacts historical growth analysis.
Future Projections: Future growth projections depend on clinical trial outcomes and regulatory approvals of its pipeline candidates. Analyst estimates are not readily available in this structured format.
Recent Initiatives: Recent initiatives include the development of Zunseogep and other pipeline candidates for immuno-inflammatory diseases.
Summary
Aclaris Therapeutics is a biopharmaceutical company with a focus on immuno-inflammatory diseases and novel therapeutics. Its strength lies in its innovative pipeline and oral drug delivery platform. Its weaknesses include its limited portfolio and dependence on clinical trials. The company needs to successfully develop and commercialize its lead product candidates to drive growth. Aclaris is a risky company that will need great science and great execution to survive, thrive and grow.
Similar Companies
- ABBV
- NVS
- LLY
- BMY
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports (limited access)
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. The AI rating is subjective and based on the available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclaris Therapeutics Inc
Exchange NASDAQ | Headquaters Wayne, PA, United States | ||
IPO Launch date 2015-10-07 | Co-Founder, CEO & Chairman Dr. Neal S. Walker D.O., M.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 61 | Website https://www.aclaristx.com |
Full time employees 61 | Website https://www.aclaristx.com | ||
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.